Biotech Values

[ghmm]

I guess that is what I get for sleeping!

Not a surprise at all that Actelion would do a deal, nor CoTherix. If I am not mistaken Schering AG has x-US Ventavis (Ilhoprost) rights and also has a right to match any bid for CoTherix (if it is a competitor). I guess Actelion doesn't qualify [don't know much about SAG]. I thought something they (Actelion) could market world-wide in PAH would be a better fit. Unless they see a lot of value in the rho-kinase inhibitor that CoTherix recently inlicensed.

With GILD buying MYOG and now this the PAH field is getting less crowded. I am still looking for United to do something at least x-US with their Inhaled/Oral if not also their sub-q and IV.

PS
I like the quizes though I often don't have a clue. Don't mind the aesthetic medicine posts (don't always read them) as follow MRX a little bit.